Allergan Stymies Generic Glaucoma Med In Patent Trial

Law360, New York (January 14, 2014, 7:56 PM EST) -- Allergan Inc. halted four competing drugmakers' attempts to produce generic versions of its glaucoma drug Lumigan on Monday, when a Texas federal judge ruled that their proposed products would infringe five patents for the brand-name drug.

Following a four-day bench trial, U.S. District Judge Michael H. Schneider entered final judgment in favor of the Irvine, Calif.-based pharmaceuticals giant, finding that the formulas for generics being developed by Sandoz Inc., Lupin Pharmaceuticals Inc., Hi-Tech Pharmacal Co. Inc. and Watson Laboratories Inc. violated the patents, and that any...
To view the full article, register now.